CDC advisers vote to recommend new preventive RSV shot for all infants
All infants under 8 months of age should get a new antibody shot to protect against severe respiratory syncytial virus, or RSV, according to a panel of independent experts that
Stay updated with breaking news from Thomas Triomphe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
All infants under 8 months of age should get a new antibody shot to protect against severe respiratory syncytial virus, or RSV, according to a panel of independent experts that
Eva Schaefer-Jansen: Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi's Second Quarter 2023 Results followed by Q&A session.
Beyfortus is approved for the prevention of RSV lower respiratory tract disease in infants and children up to 24 months of age.
SNY earnings call for the period ending June 30, 2023.
Beyfortus (nirsevimab-alip) is approved for the prevention of RSV lower respiratory tract disease in infants and children up to 24 months of age.